Brief: Ascletis Pharma Inc - First Subject Dosed In Phase Ii Clinical Trial Of Asc22 (Envafolimab) For Immune Restoration/ Functional Cure Of Hiv-1 Infection
28/06/2022 11:14
June 28 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ASCLETIS PHARMA INC - FIRST SUBJECT DOSED IN PHASE II
CLINICAL
TRIAL OF ASC22 (ENVAFOLIMAB) FOR IMMUNE RESTORATION/ FUNCTIONAL
CURE OF HIV-1 INFECTION
* ASCLETIS PHARMA INC - PHASE II CLINICAL STUDY IN CHINA IS
CURRENTLY EXPECTED TO BE COMPLETED IN EARLY 2023 WITH AN
EXPECTED ENROLLMENT OF 30 SUBJECTS
Source text for Eikon: ID:nPn7PHJgWa
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management